🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

455 results for “60” Clear

  1. -, Apalutamide placebo, JNJ-56021927

    Janssen-Cilag International N.V.

    Metastatic Hormone-sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial

  2. -, TECHNETIUM (99MTC) COMPOUNDS, -, JNJ-56021927

    Janssen-Cilag International N.V.

    High risk recurrent prostate cancer previously treated with radical prostatectomy

    phase 3 small molecule active

    1 trial

  3. 60 mg ulixacaltamide

    PRECISION BIOSCIENCES INC

    Essential Tremor

    phase 3 small molecule active

    1 trial

  4. 600 mg Ibuprofen

    United Therapeutics Europe Ltd

    Tibial Fractures

    phase 3 small molecule active

    1 trial

  5. 601 1.25mg

    Sunshine Biopharma

    Branch Retinal Vein Occlusion

    phase 3 small molecule completed

    2 trials

  6. 608

    Sunshine Biopharma

    Axial Spondyloarthritis, Non-Radiographic

    phase 3 small molecule active

    1 trial

  7. 608 Q2W

    Sunshine Biopharma

    Plaque Psoriasis Patients

    phase 3 small molecule active

    1 trial

  8. 608 Q2W

    Sunshine Biopharma

    Psoriasis

    phase 3 small molecule completed

    1 trial

  9. 608 dose

    Sunshine Biopharma

    Ankylosing Spondylitis

    phase 3 small molecule active

    1 trial

  10. 89Zr-CED88004S

    Disc Medicine

    Large B-cell lymphoma

    phase 3 small molecule active

    1 trial

  11. ACTILYSE 50mg placebo, ACTILYSE, poudre et solvant pour solution injectable et perfusion

    Pari Pharma GmbH

    intermediate-high-risk acute pulmonary embolism

    phase 3 small molecule active

    1 trial

  12. ALXN2060

    BridgeBio Oncology Therapeutics

    Symptomatic Transthyretin Amyloid Cardiomyopathy

    phase 3 small molecule completed

    1 trial

  13. ARALAST NP 60 mg/kg

    Takeda Pharmaceuticals International AG

    Chronic Obstructive Pulmonary Disease

    phase 3 mab terminated

    1 trial

  14. AZD0120, Bortezomib Hikma 3,5 mg Pulver zur Herstellung einer Injektionslösung, DARZALEX 1800 mg solution for injection, Dexamethason 1,5 mg JENAPHARM®, Kyprolis 10 mg powder for solution for infusion, Dexamethason 0,5 mg JENAPHARM®, Pomalidomide Zentiva 3 mg hard capsules, Pomalidomide Zentiva 2 mg hard capsules, Dexamethason 4 mg JENAPHARM, Kyprolis 30 mg powder for solution for infusion, Pomalidomide Zentiva 1 mg hard capsules, Pomalidomide Zentiva 4 mg hard capsules, Kyprolis 60 mg powder for solution f

    AstraZeneca AB

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  15. AZD0780 Placebo, AZD0780

    AstraZeneca AB

    Heterozygous familial hypercholesterolaemia

    phase 3 small molecule active

    1 trial

  16. AZD0780, AZD0780 Placebo

    AstraZeneca AB

    Hyperlipidemia, Atherosclerotic cardiovascular disease

    phase 3 small molecule active

    1 trial

  17. AZD0780, AZD0780 placebo

    AstraZeneca AB

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  18. Abraxane 5 mg/ml powder for dispersion for infusion., Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion, Fluorouracil Accord 50 mg/ml šķīdums injekcijām vai infūzijām, CALCIUM FOLINATE , GEMCITABINE ACCORD 100 mg/ml, solution à diluer pour perfusion, Oxaliplatin Accord 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Ipsen Pharma

    Metastatic Pancreatic Adenocarcinoma

    phase 3 small molecule active

    1 trial

  19. Aficamten, Tablet placebo for aficamten 5mg tablet

    Cytokinetics (Ireland) Limited

    SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

    phase 3 small molecule active

    1 trial

  20. Amlitelimab, Placebo, Amlitelimab, PIMECROLIMUS , -, TACROLIMUS

    Sanofi Pharma Bristol-Myers Squibb

    atopic dermatitis

    phase 3 small molecule active

    1 trial

  21. Atogepant, Placebo for atogepant tablets 60mg

    AbbVie Deutschland GmbH & Co. KG

    Migraine

    phase 3 small molecule active

    1 trial

  22. BAY 3427080, BAY 3427080 60 mg capsules placebo

    Bayer AG

    Vasomotor symptoms caused by adjuvant endocrine therapy in women with, or at high risk for developing hormone-receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  23. BNT327 20 mg ml, BNT327 50 mg ml, PEMBROLIZUMAB

    Bristol-Myers Squibb / Pfizer EEIG

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  24. BNT327 50 mg ml, DURVALUMAB, BNT327 20 mg ml

    Bristol-Myers Squibb / Pfizer EEIG

    Unresectable Stage III non-small cell lung cancer without progression

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources